Huihe Healthcare, a global leading structural heart disease platform company, successfully completed its B round financing of several hundred of million of RMB. This financing was led by IDG Capital, with participation from existing shareholders Growth Capital, and Legend Star. Shanghai Sci-Tech Innovation Center Capital, Noyu Capital, and Xiangtang Venture Capital also participated in the financing, underscoring the strong recognition of Huihe Healthcare's innovative capabilities in the field of structural heart disease and the high confidence institutional investors have in the company's development.

CEC Capital Group served as the exclusive financial advisor for Huihe Healthcare in this transaction.

Founded in 2019, Huihe Healthcare is led by its founder Lin Lin, a former cardiologist with many years of experience in structural heart disease. Through performing thousands of heart valve surgeries, she identified the clinical pain points of valve devices and developed a technical direction for them. Lin Lin introduced the innovative concept and technology of "one sheath, double valves" to doctors, enabling minimally invasive surgery for patients with combined mitral and tricuspid valve diseases through endovascular means. This innovation addresses the challenges of such surgeries and helps patients to regain a new lease on life.